Clinical trials: Metastasis Colorectal Cancer
Hepatic Metastasis of Colorectal Cancer
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
- Trial name
- NCT04202978
- Testing
- Camrelizumab, Apatinib Mesylate, Capecitabine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhongshan Hospital Xiamen University
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine…
- Trial name
- NCT00838578
- Testing
- KRN330, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Colon Cancer Liver Metastasis
Perioperative Treatment of Resectable Liver Metastases
This randomized, controlled, multicenter, non-comparative phase II trial compares an intensified perioperative treatment of patients with resectable synchronous or metachronous colorectal liver metastases to primary surgery and…
- Trial name
- PERIMAX (NCT01540435)
- Testing
- Bevacizumab
- Sponsor
- University of Regensburg
Colorectal Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have…
- Trial name
- STELLAR-303 (NCT05425940)
- Testing
- XL092, Atezolizumab, Regorafenib
- Where
- 133 sites in United States, Australia and 14 more
- Volunteers
- 901 people
- Sponsor
- Exelixis
Metastatic Colorectal Cancer (CRC)
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance
This study is a prospective, single-arm, multicenter exploratory clinical study aimed at evaluating the efficacy and safety of Fruquintinib combined With Serplulimab and chemotherapy as first-line treatment for RAS/BRAF-mutated…
- Trial name
- NCT07622550
- Testing
- Serplulimab+Fruquintinib+XELOX
- Where
- 16 sites in China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Colorectal Cancer
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- BEBYP (NCT00720512)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 21 sites in Italy
- Volunteers
- 184 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer, Metastatic Cancer
Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002692
- Testing
- fluorouracil, isolated perfusion, leucovorin calcium
- Where
- United Kingdom
- Volunteers
- 312 people
- Sponsor
- Medical Research Council
Colon Cancer
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
This is a research study to test whether two immunotherapy drugs-cemiplimab and fianlimab-can safely and effectively shrink colon tumors before surgery in people with stage II-III colon cancer that has not spread to other parts…
- Trial name
- NACho (NCT07224022)
- Testing
- Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
- Volunteers
- 24 people
- Sponsor
- John Strickler, M.D.
Metastatic Colorectal Cancer
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
HS-CA102N-103 is a Phase 2, randomized, open label study to evaluate efficacy, safety, and tolerability of CA102N combined with trifluridine/tipiracil (TAS-102) compared to bevacizumab combined with TAS-102 in subjects with…
- Trial name
- NCT06039202
- Testing
- CA102N, TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Colorectal Cancer Liver Metastases
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE
Brief Summary: Some colorectal liver metastases can only be resected after inducing liver regeneration by portal vein embolization (PVE) to increase size function of the future liver remnant (FLR).
- Trial name
- DRAGON (NCT04272931)
- Testing
- Portal and Hepatic Vein Embolization
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 111 people
- Sponsor
- Maastricht University
Colorectal Cancer, Hepatic Metastases
Targeted Delivery of Chemotherapy With Ultrasound and Microbublles
The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent…
- Trial name
- SONCHIMIO (NCT03458975)
- Testing
- MRI, Perfusion CT scan, Contrast enhanced ultrasound
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Tours
Synchronous Isolated Para-aortic Lymph Node Metastasis, Colorectal Cancer
Systemic Therapy Sequenced Isolated PALND for mCRC
The study aims to estimate the efficacy and safety of systemic therapy sequenced radical surgery in treating patients with synchronous isolated para-aortic lymph node metastasis of colorectal cancer.
- Trial name
- NCT04774757
- Testing
- Para-aortic lymph node dissection
- Where
- China
- Volunteers
- 39 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Colorectal Cancer, Colorectal Cancer Metastatic
Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis
Colorectal cancer (CRC) has the third highest cancer incidence in the world. There is mounting evidence that the intestinal microbiota plays an important role in colorectal carcinogenesis.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Intestinal Parasite, Protozoan Infections
- Trial name
- NCT03173001
- Testing
- Parasitological examination
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Colorectal Cancer
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
- Trial name
- NCT02718430
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Vaximm GmbH
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Colorectal Cancer
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01190462
- Testing
- cetuximab, simvastatin, laboratory biomarker analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Leiden University Medical Center
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT05308446
- Testing
- Cetuximab, Encorafenib, Nivolumab
- Where
- 286 sites in United States, Puerto Rico
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.